Trial · NCT07907315
Pain During Heat Treatment for Lower Extremity Varicose Veins: Radiofrequency vs. Microwave
NCT07907315, Active not recruiting, Chunshui He
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pain During Heat Treatment for Lower Extremity Varicose Veins: Radiofrequency vs. Microwave. Trials, record NCT07907315. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07907315
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pain During Heat Treatment for Lower Extremity Varicose Veins: Radiofrequency vs. Microwave
- NCT number
- NCT07907315
- Status
- Active not recruiting
- Enrollment
- 130 participants, estimated
- Lead sponsor
- Chunshui He
- Conditions
- Lower Extremity Varicose Veins, Radiofrequency Ablation, Microwave Ablation, Pain Measurement
- Interventions
- Radiofrequency ablation, Microwave Ablation
- First posted
- 2026-10-30
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pain Score at Tumescent Anesthesia Injection Completion (VAS-T2) | Measured immediately after TLA injection is completed and ultrasound confirms satisfactory perivenous fluid infiltration (before ablation begins) - Intraoperative (Day 0) | Pain intensity immediately after completion of tumescent local anesthesia (TLA) injection, assessed using the Visual Analog Scale (VAS). VAS is a clinical assessment tool that quantifies pain intensity using a linear scale approximately 10 centimeters long. The two ends of the scale are marked as "0" (no pain) and "10" (worst imaginable pain).The patient reports the most significant pain experienced during the entire TLA injection phase (from the first puncture to completion of injection). |
| Primary | Pain Score During Catheter Ablation (VAS-T3) | Measured immediately after completion of GSV trunk ablation and withdrawal of the ablation catheter | Pain intensity during the endovenous ablation phase, assessed using the Visual Analog Scale (VAS). The patient reports the most significant pain experienced during the entire ablation phase (from activation of the ablation device to completion of great saphenous vein trunk ablation).Visual Analog Scale (VAS): Minimum = 0, Maximum = 10. Higher scores indicate worse outcome (greater pain intensity). A score of 0 represents "no pain" and a score of 10 represents "worst imaginable pain." |
| Secondary | Intraoperative Pain Trajectory (Group × Time Interaction) | Assessed at four time points: T1 (immediately after sheath placement), T2 (immediately after TLA injection), T3 (immediately after ablation completion), and T4 (immediately after procedure completion) | Overall pattern of intraoperative pain across the four procedural time points, assessed to determine whether the pain trajectory differs between RFA and MWA groups. This is a composite measure derived by aggregating VAS scores from all four time points into a single repeated-measures model.VAS score (0-10 cm) analyzed as a repeated measure; reported as the group × time interaction effect (F-statistic and p-value) from a linear mixed effects model. VAS scores from T1, T2, T3, and T4 will be combined using a linear mixed effects model (LMM) with fixed effects for group, time, and group × time interaction, and random effects for individual patients. The reported value is the group × time interaction effect, which indicates whether the pain trajectory differs between groups. |
| Secondary | TLA Total Injection Volume | Recorded during the TLA injection phase | Total volume of tumescent local anesthesia (TLA) solution injected during the procedure.Milliliters (mL) |
| Secondary | RFA Ablation Energy Parameters | Intraoperative (Day 0); recorded during the ablation phase | Device-specific energy parameters for the RFA group, including temperature achieved.Temperature (°C) |
| Secondary | MWA Ablation Energy Parameters | Recorded during the ablation phase | Device-specific energy parameters for the MWA group, including power output .Power (Watts) |
| Secondary | Postoperative Pain at 2 Hours | Postoperative 2 hours | Pain intensity at rest in the treated leg at 2 hours after procedure completion.VAS score (0-10 cm) |
| Secondary | Postoperative Pain at 24 Hours | Postoperative 24 hours (Day 1) | Pain intensity at rest in the treated leg at 24 hours after procedure completion.VAS score (0-10 cm),Visual Analog Scale (VAS): Minimum = 0, Maximum = 10. Higher scores indicate worse outcome (greater pain intensity) |
| Secondary | Postoperative Pain at 7 Days | Postoperative 7 days (Day 7) | Pain intensity at rest in the treated leg at 7 days after procedure completion.VAS score (0-10 cm) |
| Secondary | Postoperative Pain at 30 Days | Postoperative 30 days (Day 30) | Pain intensity at rest in the treated leg at 30 days after procedure completion.VAS score (0-10 cm),VAS: Minimum = 0, Maximum = 10. Higher scores indicate worse outcome (greater pain intensity) |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07907315
GET https://conductscience.org/api/trials/v1/NCT07907315/registered